Close
Adam Spicer regularly tries high-stakes cases involving complex scientific, medical, regulatory, and reputational issues in some of the country’s most difficult jurisdictions. He has been recognized for his trial work by such publications as Chambers USA, Legal500, Law360, and others. Adam focuses his practice on representing pharmaceutical, medical device, agricultural, and chemical manufacturers in both mass tort and single plaintiff cases throughout the country. He also has significant experience representing pharmaceutical and medical device clients in state Attorneys General actions.
Noted by one client as a “dynamo and a very formidable adversary,” as well as a “thoughtful advocate with impressive judgment and tireless dedication,” Adam is particularly well-known for his ability to develop and communicate compelling stories on behalf of clients. He also has a well-earned reputation for his ability to work collegially with lawyers in other firms as part of a trial team or Virtual Law Firm. One such lawyer was quoted in Law360 as saying, “I have been lucky to work with [Adam] during several trials. Adam is like the eye of a hurricane – he stays calm in the midst of chaos and strategically assesses trial themes. And he’s a nice guy!”
Prior to becoming an attorney, Adam served on active duty in the United States Navy from 1998-2002. He received Navy and Marine Corps Achievement Medals, a Navy Letter of Commendation, and Navy Sea Service Awards.
Recent Publications
Co-Author, “Coordination among Federal Prosecutors, Regulators, and Civil Enforcers: Questions Abound, “ABA, Section of Litigation Mass Torts Newsletter, Vol. 14, No. 3. Summer 2016.
Co-Author, “Social Media and the Legal Profession—Where Is the Ethical Line?” ABA Section of Litigation Mass Torts News & Developments, March 31, 2015.
Author, “Increasing Coordination among Federal Prosecutors, Regulators, and Civil Enforcers,” ABA Section of Litigation, Mass Torts Newsletter, Summer 2015.
Author, “Effective Strategies for Neutralizing the Adverse Prescribing or Treating Physician at Deposition and Trial,” DRI’s 30th Annual Drug and Medical Device Seminar, May 2014.
Author, “FDA Considers Changes to its OTC Drug Review, Potentially Affecting Over 300,000 Drug Products,” ABA Section of Litigation Mass Torts Newsletter, April 30, 2014.
Co-Author, “Mississippi Jury Instructions for Product Liability Claims and Defenses,” PLAC Handbook of Jury Instructions, 2009.
Recent Speaking Engagements
Speaker, "Embracing the New Normal: Best Practices for Efficient and Successful Virtual/Remote Trial Practice," ACI's Annual Conference on Drug and Medical Device Litigation, December 2020.
Panelist, “Recent Trends in the American Legal System,” ABA Regional Continuing Legal Education (CLE), Bristol-Myers Squibb Company, Lawrence Township, N.J., October 2017.
Speaker, “Connecting the Voir Dire and Opening Statement … And Why it Matters,” Trial Practice Seminar, FedEx Worldwide Headquarters, Memphis, Tenn., May 28, 2015.
Speaker, “Potential Criminal and Regulatory Implications of Pharmaceutical, Biotechnology, and Medical Device Products Liability Lawsuits,” Continuing Legal Education for global healthcare client, April 21, 2015.
Panelist, "The Dos and Don'ts of Trial Practice," ABA Environmental, Mass Torts & Products Liability Litigation Committees' Joint CLE Seminar, Aspen, Colo., 2015.
Speaker, DRI’s 30th Annual Drug and Medical Device Seminar, Washington, D.C., “Effective Strategies for Neutralizing the Adverse Prescribing or Treating Physician at Deposition and Trial,” May 2014.
back
